Stock Events

Stock Events

enGene Therapeutics 

$2.47
3
+$0.08+3.35% Friday 17:17

Statistics

Day High
2.23
Day Low
2.23
52W High
4.2
52W Low
0.57
Volume
4,969
Avg. Volume
-
Mkt Cap
128.48M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.73
-0.6
-0.48
-0.35
Expected EPS
-0.470381
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-234.6MNet Income

Analyst Ratings

21.08Average Price Target
The highest estimate is 30.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENGNW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, overlapping with enGene's focus on gene therapy for gastrointestinal diseases.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, which competes directly with enGene's gene therapy technologies.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is known for its work in CRISPR-Cas9 gene editing, a technology that can be applied similarly to enGene's gene delivery platforms.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is another key player in the CRISPR gene editing sector, directly competing with enGene's approach to gene therapy.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, similar to enGene's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, a field closely related to gene therapy, impacting similar therapeutic areas as enGene.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, competing in the broader genetic medicine space with enGene.
uniQure N.V.
QURE
Mkt Cap961.7M
uniQure is involved in developing gene therapies for patients with severe genetic diseases, directly competing with enGene's therapeutic approaches.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the same innovative sector as enGene.

About

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
CEO
Mr. Ronald H. W. Cooper
Employees
56
Country
Canada
ISIN
CA29286X1197

Listings

F
DE
S0N0.F
F
DE
S0N.F
XNAS
US
ENGNW
XNAS
US
ENGN

0 Comments

Share your thoughts

FAQ

What is enGene Therapeutics stock price today?▼
The current price of ENGNW is $2.47 USD — it has increased by +3.35% in the past 24 hours. Watch enGene Therapeutics stock price performance more closely on the chart.
What is enGene Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange enGene Therapeutics stocks are traded under the ticker ENGNW.
Is enGene Therapeutics stock price growing?▼
ENGNW stock has risen by +4.22% compared to the previous week, the month change is a +6.93% rise, over the last year enGene Therapeutics has showed a +268.6% increase.
What is enGene Therapeutics market cap?▼
Today enGene Therapeutics has the market capitalization of 128.48M
When is the next enGene Therapeutics earnings date?▼
enGene Therapeutics is going to release the next earnings report on June 12, 2026.
What were enGene Therapeutics earnings last quarter?▼
ENGNW earnings for the last quarter are -0.44 USD per share, whereas the estimation was -0.56 USD resulting in a +21.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is enGene Therapeutics revenue for the last year?▼
enGene Therapeutics revenue for the last year amounts to 0 USD.
What is enGene Therapeutics net income for the last year?▼
ENGNW net income for the last year is -234.6M USD.
How many employees does enGene Therapeutics have?▼
As of April 18, 2026, the company has 56 employees.
In which sector is enGene Therapeutics located?▼
enGene Therapeutics operates in the Health & Wellness sector.
When did enGene Therapeutics complete a stock split?▼
enGene Therapeutics has not had any recent stock splits.
Where is enGene Therapeutics headquartered?▼
enGene Therapeutics is headquartered in Montreal, Canada.